Search
News & Events
Investigational vaccine for WA's meningococcal threatPerth researchers have begun a clinical trial of an investigational Meningococcal B vaccine against the most common form of meningococcal disease in W.A.
News & Events
Potential new vaccine for WA's meningococcal threatPerth researchers are trialling a Meningococcal B vaccine that could potentially provide protection
News & Events
Beating the flu bugPerth children are being asked to volunteer for an important national study to test the effectiveness of an influenza vaccine in children.
News & Events
BHP commits $2.6 million to research focused on stopping COVID-19 spreadResearchers from The Kids Research Institute Australia will lead a world first trial to test the effectiveness of the drug interferon in stopping outbreaks of COVID-19 by reducing the infectiousness of people who contract the virus.
News & Events
Sharing the power of data at TEDx PerthDr Hannah Moore was one of WA’s brightest minds chosen to speak at TEDX Perth in November last year, presenting her insights into the power of data in fighting infectious diseases to a sold-out crowd at the Perth Concert Hall.
News & Events
First week of school visits mark official launch of the SToP TrialThe The Kids Skin Health team has a busy six weeks ahead - visiting nine communities throughout the Kimberley region of WA as part of the first school surveillance activities for the SToP Trial.
News & Events
Premature babies at greater risk of childhood infectionNew research has found children who are born even slightly premature or underweight are more likely to be hospitalised with an infection during their childhood
News & Events
Trans Tasman action to fast track rheumatic fever vaccinePrime Ministers of Australia and New Zealand have agreed to provide $3M to help fast-track the development of a vaccine against rheumatic fever.
Research
Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in AustraliaAustralia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.
Research
Modelling respiratory syncytial virus age-specific risk of hospitalisation in term and preterm infantsRespiratory syncytial virus (RSV) is the most common cause of acute lower respiratory infections in children worldwide. The highest incidence of severe disease is in the first 6 months of life, with infants born preterm at greatest risk for severe RSV infections.